Akebia Q3 net loss $14.5M, Auryxia rev $40.1M, vadadustat PDUFA Mar 27, 2024

Akebia Therapeutics, Inc.

2023-Q3 EPS reported -$0.28 revenue$138,427,000

Net loss improved to $14.5M from $54.1M in Q3 2022; total revenue $42.0M, down from $48.7M.
Auryxia net product revenue $40.1M (Q3 2022: $42.0M); FY 2023 guidance reaffirmed at $170-175M.
Vadadustat NDA resubmission accepted; PDUFA date set for March 27, 2024 for anemia in dialysis CKD.
Vadadustat approved in 36 countries including Australia and Taiwan; five posters at Kidney Week 2023.
Modified Pharmakon loan: principal payments deferred to Oct 2024, maturity extended to March 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Akebia Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $42.0 million, net income $14.5 million. Guidance reaffirmed.

Period: third quarter ended September 30, 2023
Revenue: $42.0 million
Net income: $14.5 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenues were $42.0 million for the third quarter of 2023, compared to $48.7 million for the third quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-23-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.